V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

Description: V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Merck is developing V503, a nine-valent HPV vaccine; like Gardasil, this vaccine is being developed in partnership with CSL, from which Merck is licensing VLP technology. Both V503 and Merck's current vaccine Gardasil have a similar mechanism of action, consisting of VLPs combined with aluminum salt adjuvant, delivered as an IM injection over a three-dose course. Merck has recently registered a Phase III trial to assess the immunogenicity of V503 given over a two-dose course (Merck, NCT01984697).

Scope

- Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on V503 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for V503 for the top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Canada and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HPV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of V503 performance
- Obtain sales forecast for V503 from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Canada and Australia)

Contents: 1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Vaccination Recommendations and Coverage Rates
4.1 Vaccination Recommendations Overview

5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment

6 Unmet Need and Opportunity
6.1 Overview
6.2 Protection against Multiple HPV Types
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Vaccine Coverage Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Perception of Vaccine Safety
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Awareness of HPV Vaccination
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Affordability of HPV Vaccines
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Coverage of HPV Types Prevalent in Certain Populations
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 Vaccine Compliance Rates
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
6.9 Lifelong Protection from HPV Infection Not Established
6.9.1 Unmet Need
6.9.2 Gap Analysis
6.9.3 Opportunity
6.10 Ongoing Need for Cervical Cancer Screening
6.10.1 Unmet Need
6.10.2 Gap Analysis
6.10.3 Opportunity

7 Pipeline Assessment
7.1 Overview
7.2 Promising Vaccines in Clinical Development

8 V503
8.1 Overview
8.2 Immunogenicity
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
9 Appendix

9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccine Approval versus Routine Schedule Inclusion
9.4.3 General Pricing Assumptions
9.4.4 Individual Drug Assumptions
9.4.5 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 About the Author(s)
9.6.1 Author(s)
9.6.2 Therapy Area Director
9.6.3 Global Head of Healthcare
9.7 About Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Histological Progression Towards Cervical Cancer
Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
Table 3: HPV Vaccine Recommendation Agencies by Country
Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014
Table 5: Marketed Vaccines for HPV, 2014
Table 6: Overall Unmet Needs - Current and Future Level of Attainment
Table 7: HPV Vaccines - Phase Pipeline, 2014
Table 8: Product Profile - V503
Table 9: V503 SWOT Analysis, 2013
Table 10: Global Sales Forecasts ($m) for V503, 2012-2022
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/2881902/](http://www.researchandmarkets.com/reports/2881902/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2881902/">http://www.researchandmarkets.com/reports/2881902/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6IYJDA</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB9853308313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World